DCPIB

VRAC抑制剂；抑制牛肺动脉内皮细胞中的ICl,swell（IC50=4.1µM）；抑制LRRC8A（IC50=20.9µM）并在20µM时抑制TIME细胞中鞘氨醇-1-磷酸诱导的LRRC8A对cGAMP的摄取；抑制表达人类通道的COS-7细胞中的K2P18.1/TRESK、K2P3.1/TASK1和K2P9.1/TASK3（IC50s分别为0.14、0.95和50.72µM）；在10µM时激活表达人类通道的COS-7细胞中的K2P2.1/TREK1和K2P4.1/TRAAK通道；20µg/kg脑池内给药可减少由MCAO诱发的大鼠脑缺血模型中的梗塞面积和神经功能缺损评分。A VRAC inhibitor; inhibits ICl,swell in bovine pulmonary artery endothelial cells (IC50 = 4.1 µM); inhibits LRRC8A (IC50 = 20.9 µM) and inhibits sphingosine-1-phosphate-induced cGAMP uptake by LRRC8A in TIME cells at 20 µM; inhibits K2P18.1/TRESK, K2P3.1/TASK1, and K2P9.1/TASK3 in COS-7 cells expressing the human channels (IC50s = 0.14, 0.95, and 50.72 µM, respectively); activates K2P2.1/TREK1 and K2P4.1/TRAAK channels in COS-7 cells expressing the human channels at 10 µM; intracisternal administration reduces infarct area and neurological deficit scores in a rat model of cerebral ischemia induced by MCAO at 20 µg/kg.分子式C22H28Cl2O4分子量427.4O=C(CCCOC1=C(Cl)C(Cl)=C(C(C(CCCC)(C2CCCC2)C3)=O)C3=C1)O